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Abstract 1 
Background: Colon cancer is the most aggressive form of cancers, that causes 0.5 2 
million deaths per year around the globe. Targeting colon cancer by conventional 3 
therapeutic options elicits toxicity. Traditional medicines take lead to alleviate the 4 
existing clinical challenges. 5 
Objective: To investigate anti bacterial activity against Helicobacter Pylori and in vitro 6 
anti colon cancer activity by Acacia nilotica extract (ACE) and its active constituent 7 
pyrogallol. 8 
Methods: Pyrogallol isolated from A. nilotica by column chromatography and HPLC and 9 
structure was elucidated by spectral analysis. Antibacterial activity was done by flow 10 
cytometry. Cyto-toxicity was measured by MTT assay. Apoptotic morphology and 11 
nuclear fragmentation was assessed with AO/ethidium bromide and DAPI staining. DNA 12 
fragmentation was done by electrophoresis. Western blot used to analyze the molecular 13 
mechanism of apoptosis. Cell cycle arrest was determined using flow cytometry of 14 
propidium iodide stained cells. Cell migration was determined by wound healing assay. 15 
Results: ACE (20 µg/ml) and pyrogallol (10 µg/ml) treatment reduced the survival of 16 
H.pylori at 61% and 62% respectively. MTT results shows that HT-29 cells are more 17 
sensitive to pyrogallol with an IC50 value of 35µg/ml compare to ACE. Pyrogallol treated 18 
HT-29 cells reached dead state i.e. late apoptotic state with severe nuclear fragmentation. 19 
Pyrogallol induced apoptosis by simultaneous down regulation of Bcl-2 and up regulation 20 
of BAX and cytochrome c. Pyrogallol arrested HT-29 cells in S and G2/M phase of cell 21 
cycle. Further pyrogallol exhibited marked anti metastatic potential by inhibiting the 22 
migration of HT-29 cells dose dependently. 23 
Conclusion: Both ACE and pyrogallol repressed the growth of H.pylori and as 24 
significant anti colon cancer agent. 25 
Keywords: Acacia nilotica, pyrogallol, Helicobacter pylori, colon cancer, apoptosis 26 
27 
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1. INTRODUCTION 1 
 2 
Colon cancer is one of the leading causes of cancer related death worldwide with 3 
0.5 million deaths every year and its incidence continues to rise in the eastern world [1]. 4 
As per the American Cancer Society, there will be an estimated 140,250 new cases of 5 
colon cancer and 27,390 men and 23,240 women will die from colon cancer in 2018 [2]. 6 
The evolution of colon cancer seems to follow a predictable pattern of histological 7 
changes and concurrent genetic and epigenetic changes, which ultimately provide a 8 
growth advantage resulting in the clonal expansion of transformed cells. At least three 9 
forms of genomic instability contribute to colon cancer, including microsatellite 10 
instability, chromosome instability, and chromosomal translocations [3]. Surgery can be 11 
an effective primary treatment in the early stage of colon cancer, but surgical resection is 12 
unsatisfactory in cases of metastasis and recurrence [4]. Chemotherapeutic agent 5-13 
flurouracil (5-FU) widely used as a first line treatment for colon cancer patients over 50 14 
years of age [5]. Due to extreme toxicity, drug resistant and inter-individual differences 15 
in response to treatment are major limitations [6]. Thus there is an urgent need on 16 
developing drug for colon cancer treatment with least toxicity and to target diverse array 17 
of colon cancer with different molecular signatures.  18 
Natural products derived from medicinal plants received attention due to their less 19 
toxicity. Natural products based cancer drugs such as vincristine, vinblastine, 20 
podophyllotoxin, taxol etc. are renowned examples. These discoveries inspired by 21 
traditional and folk medicine clearly gives an indication that natural products are the 22 
future source for lead structures, and these will be used as templates for the development 23 
of more promising novel compounds with improved biological properties. Therefore, it is 24 
essential to use the available traditional knowledge and investigate the active plant 25 
extracts for the isolation of new, less toxic and highly efficacious molecules. The genus 26 
Acacia belongs to the family Leguminosae. Acacia used as an antiseptic, demulcent, 27 
purgative [7] and an effective tonic in diabetes mellitus [8]. Several species of Acacia 28 
have been proven as an effective medicine in the treatment of a cough, toothache, 29 
diarrhea, dysentery, jaundice, and skin disorders [9-12]. Acacia containing more than 30 
1350 species and various bioactive compounds such as (+) -catechin, (−)-epicatechin, 31 
(−)-epicatechin-3-O-gallate, epigallocatechin-3-O-gallate, quercetin, and (+)-cyanidanol 32 
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[13]. Various parts of Acacia possess significant antibacterial and antifungal properties 1 
[14, 15]. Compounds identified from Acacia species are known to modulate various 2 
signaling pathways in breast and prostate cancer [16, 17].  3 
Among Acacia species, Acacia nilotica (also known as Gum Arabic tree, Babul, 4 
Egyptian thorn, or Prickly Acacia) is widely cultivated in the Indian subcontinent and 5 
also found on lateritic soil in the Himalayan foothills [13]. A. nilotica is also reported to 6 
be effective against multidrug-resistant strains of bacteria and fungus causing nosocomial 7 
and community-acquired infections [18]. A. nilotica reported to be an effective anti 8 
cancer agent in different tumor model. γ-Sistosterol isolated from A. nilotica induces 9 
apoptosis and cell cycle arrest in breast cancer (MCF-7) and lung cancer (A549) cells 10 
[19]. Phenolic compounds derived from Egyptian A. nilotica reported for arresting the 11 
proliferation of melanoma cells [20]. A. nilotica shown to be an effective anti cancer 12 
agent against Dalton’s ascitic lymphoma [21]. Our previous study shows that A. nilotica 13 
extract can induce significant cell death in both MDA-MB-231 and HEp-2 cells [22]. 14 
However, the role of A. nilotica and its active constituent pyrogallol on colon cancer is 15 
not yet reported. As per our knowledge herein we report for the first time in vitro 16 
anticancer activity of A. nilotica extract and its active constituent pyrogallol on colon 17 
cancer cells and their role in inducing apoptosis and cell cycle arrest.   18 
 19 
 20 
 21 
22 
  
 6 
2. Materials and Methods 1 
2.1. Plant Material 2 
 3 
The fresh leaves of A. nilotica were collected from the Foundation for 4 
Revitalization of Local Health Traditions, Bangalore, India (Latitude 12.9715987; 5 
Longitude 77.5945627). 6 
 7 
2.2. Preparation of A. nilotica Extract (ACE) 8 
 9 
Extraction was done as described earlier [22]. Briefly, fresh leaves of A. nilotica 10 
was collected and washed in tap water. It was shade dried for 10 days and made into a 11 
fine powder of 40 mesh in size using the laboratory mill. 100 g of powder was filled in a 12 
clean flat-bottomed glass container and soaked in 70% acetone for 72 h. The container 13 
with its content was sealed and kept for a period of three days accompanying occasional 14 
shaking and stirring. Extract was filtered using whatman no. 1 filter paper and it was 15 
dried at room temperature. 16 
2.3. Isolation and Characterization of Pyrogallol 17 
ACE was fractionated by column chromatography using different proportion of 18 
ethyl acetate and hexane and fractions were subjected to HPLC and pyrogallol was 19 
isolated based on retention time and absorbance of reference standard pyrogallol (Sigma 20 
Aldrich, Louis MO, USA). Further structure of pyrogallol was elucidated by spectral 21 
analysis such as FTIR, 1H NMR, 13CNMR, GCMS, LCMS and XRD. 22 
2.4. Effect of ACE and Pyrogallol on Helicobacter pylori Survival by Flow 23 
Cytometry Analysis  24 
Bacteriostatic eﬀect of ACE and pyrogallol on antibiotic resistant H.pylori 26695 25 
was determined by flow cytometry using annexin V-FITC and propidium iodide. H. 26 
pylori (1x105 cells/ ml) was treated with ACE (20 µg/ml) and pyrogallol (10 µg/ml) 27 
separately and incubated for 3 h. Then, the treated cells was harvested three times at 1 hr 28 
intervals, washed and suspended in PBS. These cells were then centrifuged at 2000 g for 29 
10 min in order to prepare cell pellet. To the cell pellet 1ml of annexin V-FITC staining 30 
solution (Strong Biotech Co., Taipei, Taiwan) was added and incubated for 10-15 min at 31 
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25˚C. Then cells were analyzed for cell cycle by flow cytometer (FACS verse, BD 1 
Bioscience, USA).  2 
2.5. In Vitro Anti cancer Activity 3 
2.5.1. Cell culture 4 
 The human colon cancer cell HT-29 and normal colon cell CRL-1831 cells were 5 
purchased from the National Center for Cell Sciences (NCCS), Pune, India. The cells 6 
were maintained in Dulbecco’s modified eagles medium (DMEM) supplemented with 7 
2mM l-glutamine and balanced salt solution (BSS) adjusted to contain 1.5 g/L Na2CO3, 8 
0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM l-glutamine, 1.5 g/L 9 
glucose, 10 mM (4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid) (HEPES) and 10 
10% fetal bovine serum (GIBCO, USA). 1% antibiotics (penicillin/streptomycin) mixture 11 
was added. The cells were maintained at 37◦C with 5% CO2 in a humidified CO2 12 
incubator.  13 
2.5.2. Evaluation of Cytotoxicity  14 
 Cytotoxicity of ACE and pyrogallol was evaluated by MTT assay. HT-29 and 15 
CRL-1831 cells were cultured (1×104cells/well) in a 96-well plate for 48 h into 80% 16 
confluence. Then medium was replaced with fresh medium containing 20, 40, 60, 80 and 17 
100 µg/ml pyrogallol or ACE, and the cells were further incubated for 24 h. Then culture 18 
medium was removed, and 100 µl of the MTT (3-4,5-dimethylthiozol-2-yl)-3,5-diphenyl 19 
tetrazolium bromide) (Hi-Media) solution was added to each well and incubated at 37◦C 20 
for 4 h. After removal of the supernatant, 50 µL of DMSO was added to each well and 21 
incubated for 10 min to solubilize the formazan crystals. The absorbance was measured at 22 
620 nm in an ELISA multi well plate reader (Thermo Multiskan EX, USA). Absorbance 23 
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of control (without treatment) considered as 100% cell survival. Doxorubicin was used as 1 
positive drug control. 2 
2.5.3. Fluorescence Microscopic Analysis of Apoptosis and Nuclear Fragmentation  3 
 CRL-1831 and HT-29, 1X105 cells/ml each, were seeded separately in 96 well 4 
plates and allowed to adhere firmly. The cells were then treated with different 5 
concentration of ACE or pyrogallol (25, 50 and 100 µg/ml). After 24 h treatment, 20 µl 6 
of trypsin was added into each well. Trypsinized cell suspension washed with phosphate 7 
buffered saline (PBS) and 25 µl cell suspension was transferred to glass slides. Dual 8 
fluorescent staining solution (1 µl) containing 100 µg/ml acridine orange/ethidium 9 
bromide (AO/EB, Sigma, St. Louis, MO) was added to each suspension and then covered 10 
with a coverslip. The morphology of apoptotic cells was examined and visualized under a 11 
fluorescence microscope (Nikon Eclipse, Inc, Japan) at 400× magnification with an 12 
excitation filter at 480 nm. Likewise the cells were seeded on glass coverslip in a 24-well 13 
plate and treated with ACE or pyrogallol (25, 50 and 100 µg/ml) for 24 h. Then cells 14 
were fixed and permeabilised with 0.2% triton X-100 (50 μl) for 10 min at room 15 
temperature. Further cells were incubated for 3 min with 10 μl of DAPI by placing a 16 
coverslip over the cells to enable uniform spreading of the stain. The cells were then 17 
observed under fluorescent microscope (Nikon Eclipse, Inc, Japan). 18 
2.5.4. DNA Fragmentation by Agarose Gel Electrophoresis  19 
DNA ladder formation was done as described elsewhere. CRL-1831 and HT-29 20 
were seeded in 6-well plates at a concentration of 1x106 cells per ml of medium. Then 21 
cells were treated with ACE or pyrogallol (25, 50 and 100 µg/ml). Cells were harvested 22 
after 24 h of treatment and DNA fragmentation was assessed by gel electrophoresis. 23 
 24 
 25 
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2.5.5. Western Blot Analysis  1 
The whole cell lysate was prepared from ACE or pyrogallol (25, 50 and 100 2 
µg/ml) treated HT-29 cells after 24 hr as described earlier [23]. Then cell lysate were 3 
resolved in a 10% SDS polyacrylamide gel electrophoretically and electro transferred 4 
onto a nitrocellulose membrane. Then immunoblots were probed with Bcl-2, Bax and 5 
cytochrome c antibodies and visualized with the NBT/BCIP chromogenic substrate and 6 
documented. 7 
2.5.6. Cell Cycle Analysis 8 
HT-29 (2×10 5cells/10 cm dish) cells were treated with 25, 50 and 100 µg/ml of 9 
pyrogallol or ACE for 24h. Then cells were harvested by centrifugation, washed with ice-10 
cold PBS, and then resuspended with ice-cold 70% ethanol overnight. Further, the cells 11 
were treated with 10 μg/ml of RNase at 37˚C, then spun down and stained with 40 µg/ml 12 
of propidium iodide (PI) for 30 min. The DNA content was then measured by ﬂow 13 
cytometry (FACS, BD Bioscience). 14 
2.5.7. Wound Healing Assay 15 
HT-29 cells were seeded in 35 mm, collagen-coated dishes, at a density of 4X105 16 
cells/cm2. Upon conﬂuence, the monolayer cell cultures were treated with different 17 
concentration of ACE or pyrogallol (25 and 50 µg/ml). After 24 h of treatment, cell 18 
cultures were scratched with a sterile 200 µl tip to stimulate a wound in vitro. The cells 19 
were incubated in a 2% low serum medium and migration of cells across the scratch 20 
wound was measured from wounding up to complete coverage of the scratch. The cells 21 
were photographed under phase-contrast microscopy and scratch wound areas were 22 
measured using NIH Image J software. The mean scratch wound area was calculated 23 
from three independent experiments.  24 
2.6. Statistical Analysis 25 
 The data presented mean ± STD. All the in vitro experiments were done in 26 
triplicate of three independent experiments. The statistical software SPSS version 17.0 27 
was used for the analysis. P value <0.01 was considered significant. 28 
 29 
30 
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3. RESULTS 1 
3.1. Isolation and Characterization of Pyrogallol 2 
Acetone extract of A.nilotica (ACE) was fractionated by column chromatography 3 
using different proportion of ethyl acetate and hexane. Totally 15 fractions were collected 4 
and fractions were checked for anti bacterial against Helicobacter pylori. By adopting 5 
bioassay guided approach for active principle isolation, active anti bacterial fraction was 6 
subjected to HPLC for pyrogallol isolation. FT-IR spectrum showed the broad peak at 7 
3321.42cm-1. This is due to the presence of phenolic OH group present on the pyrogallol 8 
then the aromatic stretching C-H bond appeared at 3093.82cm-1. The aromatic ring C=C 9 
stretching bond shown in 1620, 1517 and 1481cm-1. In plane of O-H bond exhibiting at 10 
bending mode at 1359 cm-1 and C-O stretching appeared at 1242 cm-1 which again 11 
confirmed the presence of C-O. The out of plane of C-H bending shown at 838.767cm-1 12 
and the out of plane O-H bond about 697 cm-1 (Fig. 1A). The molecular weight of 13 
pyrogallol (126.11) identified by GCMS analysis (Fig. 1B). 1H NMR, a broad singlet 14 
appeared at δ 6. 25 ppm, which represents the presence of hydroxyl moiety next the 15 
aromatic proton, appeared at δ 7.26-6.46 ppm which represents the presents of aromatic 16 
protons. 13C NMR the peaks appeared at δ 102. 6, δ 114.9, δ 126. 5 and 139.7 ppm these 17 
again confirmed the presence of the aromatic carbon shown in the pyrogallol unit (Fig. 18 
1C and D). HPLC profile purified compound displayed a sharp intense peak at retention 19 
time 4.028 and it is compared with reference pyrogallol (Fig. 1E). LCMS data revealed 20 
the molecular mass of isolated pyrogallol and it is also in agreement with GCMS (Fig. 21 
1F). XRD pattern of pyrogallol powder revealed that it is according to the line width of the 22 
plane and refraction peak of m.p. 131° - 135°C. F (Fig. 1G). Further XRD patterns of the 23 
pyrogallol in diffraction angle range 2θ = 3 - 80° using monochromatic Cu ka radiation 24 
reveals presence of hydroxyl group of pyrogallol and can adopt different confirmations. 25 
Our result is in agreement with Thakuria et al. [24]. 26 
3.2. Flow Cytometry Analysis of Helicobacter pylori Inhibition 27 
  Drug resistant H. pylori was treated with ACE (20 µg/ml) or pyrogallol (10 28 
µg/ml) and observed for percent of cells attained the bacteriostatic state. Flow cytometry 29 
data shows that the viability of H. pylori is decreased in time dependent manner viz. 37% 30 
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(1h), 42% (2h) and 61% (3h) upon the treatment of ACE whereas pyrogallol (10 µg/ml) 1 
also reduced viability of H. pylori viz. 47% (1h), 57% (2h), and 62% (3h). This data 2 
clearly indicates that pyrogallol (10 µg/ml) and ACE (20 µg/ml) have similar potency 3 
against H. pylori (Fig. 2). 4 
3.3. Cytotoxicity of ACE or Pyrogallol on HT-29 and CRL-1831 cells 5 
HT-29 and CRL-1831 cells were treated with different concentration (20, 40, 60, 6 
80 and 100 µg/ml) of ACE or pyrogallol for 24 h. Viability of both HT-29 and CRL-1831 7 
are reduced in a dose dependent manner (Fig. 3). IC50 value of ACE on HT-29 and CRL-8 
1831 cells is >100 µg/ml. Whereas IC50 value of pyrogallol on HT-29 and CRL-1831 9 
cells are 35 µg/ml and > 100 µg/ml respectively. HT-29 cells are more sensitive to 10 
pyrogallol than ACE and this data clearly evidences the anti-proliferative potential of 11 
pyrogallol. 12 
3.4. Role of ACE or Pyrogallol on Apoptosis and Nuclear Fragmentation 13 
The morphological changes of the CRL-1831 and HT29 cells-treated with ACE or 14 
pyrogallol for 24 h at concentration of 25, 50 and 100 μg/ml were analyzed by AO/EB 15 
fluorescence staining. ACE treatment exhibited pronounced morphological changes in 16 
HT-29 cells compared to CRL-1831 cells. HT-29 cells reached late apoptotic state where 17 
the irreversible damage occurs. Further DAPI staining infers that 24 h of ACE/pyrogallol 18 
treatment elicits significant apoptotic morphology such as cell shrinkage, nuclear 19 
condensation and fragmentation and formation of apoptotic bodies in HT-29 cells 20 
compare to CRL-1831 cells (Fig. 4A and B).  21 
3.5. DNA Fragmentation Ability of ACE or Pyrogallol on CRL-1831 and HT29 cells 22 
To ensure the DNA targeting ability of ACE or Pyrogallol, CRL-1831 and HT-29 23 
cells were treated with different concentration (25, 50 and 100 μg/ml) of ACE or 24 
Pyrogallol for 24 h and observed for DNA damage. ACE or Pyrogallol induced profound 25 
dose dependent DNA ladder formation in HT-29 cells compare to CRL-1831 (Fig. 5).  26 
27 
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3.6. Molecular Mechanism of Inducing Apoptosis by ACE or Pyrogallol in HT-29 1 
cells 2 
To investigate the role of ACE or pyrogallol on pro apoptotic and anti apoptotic 3 
signaling, we analyzed the expression level of Bcl-2, BAX and cytochrome c by 4 
immunoblot. ACE or pyrogallol treatment down regulates the expression of Bcl-2 and 5 
up-regulate the expression of BAX and cytochrome c (Fig. 6A and B). This data reveals 6 
that apoptosis induction in HT-29 cells by ACE or pyrogallol mediated by simultaneous 7 
up regulation of BAX and cytochrome c and down regulation of Bcl-2. 8 
 9 
3.7. Efficacy of ACE or Pyrogallol on HT-29 Cell Cycle 10 
HT-29 cells were treated with different concentrations (25, 50, and 100 μg/ml) of 11 
ACE or pyrogallol for 24 h and analyzed for cell cycle arrest by flow cytometry. ACE or 12 
pyrogallol treatment resulted in dose dependent reduction of number of cells in S and 13 
G2/M phase (Fig. 6A and B). Data indicates that ACE or pyrogallol halt DNA synthesis 14 
and subsequent mitosis in HT-29 cells.  15 
3.8. Effect of ACE or Pyrogallol on HT-29 Migration by Wound Healing Assay 16 
Cancer cell migration is an hallmark of metastasis. HT-29 cells were treated with 17 
different concentration (25 and 50 µg/ml) of ACE or pyrogallol for 24 h and observed for 18 
migration. Both ACE and pyrogallol elicited significant dose dependent migration 19 
inhibitory activity compared to untreated control (Fig. 7A and B).  20 
21 
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4. Discussion 1 
Focus on complementary and alternative medicine has been emerged rapidly for 2 
the past two decades. Active ingredients present in natural resources possess significant 3 
biological activity to combat deadliest form of diseases such as cancer. Natural products 4 
derived from medicinal plants attracted lots of attention since the fact that major 5 
breakthroughs in cancer drug discovery have been owed either to the natural products or 6 
the natural product scaffolds; vincristine, vinblastine, podophyllotoxin, taxol are few to 7 
be quoted. These natural products based scaffolds can be used as templates for the source 8 
for lead structures, and for the development of more promising novel compounds with 9 
improved biological properties. Therefore in this study we delineate the role of A. nilotica 10 
extract (ACE) and its active constituent pyrogallol for anti bacterial activity against 11 
helicobacter pylori and as an anti colon cancer agent in vitro. 12 
It is well known that H. pylori disrupts gastric function and induce carcinogenesis 13 
in colon. As per International Agency for Research on Cancer, H. pylori is recognized as 14 
a class I human carcinogen [25]. A possible pathogenetic mechanism involves the 15 
persistent H. pylori colonization and inflammation of the gastric mucosa, particularly 16 
when the H. pylori strains express the cytoxin-associated gene (CagA) which often 17 
results in the development of chronic atrophic gastritis and subsequently 18 
hypergastrinemia and it leads to be a possible risk factor for the development of colon 19 
cancer [26–28]. In this study we tested the efficacy of ACE and pyrogallol on survival of 20 
H. pylori. Earlier, ACE reported for inhibition of H. pylori and its minimum inhibitory 21 
concentration (MIC) was determined by agar well diffusion method [29]. In our study we 22 
used flow cytometry analysis to assess the antibacterial activity of ACE and pyrogallol 23 
since minimum inhibitory concentration (MIC) and minimum bacterial concentration 24 
(MBC) assays has limitations such as  non-quantitative, do not discriminate between 25 
bacteriostatic and bactericidal which requires quantitative assays. By using flow 26 
cytometry technique disruption of the cytoplasmic membrane of H. pylori can be 27 
monitored by membrane permeable fluorescent (Annexin FITC-A) intercalating DNA 28 
dyes and it is directly reflecting viability of a microbial culture. Noticeably flow 29 
cytometry employed by others to assess the growth inhibition of H. pylori by natural 30 
products [30]. After 3 hr of treatment with ACE (20 µg/ml) or pyrogallol (10 µg/ml) 31 
  
 14 
more than 60% of H. pylori cells reached bacteriostatic state (Fig. 2A and 2B). It is 1 
noteworthy that less dose of pyrogallol can induce prominent H. pylori cell death 2 
compare to ACE. However mechanism of inducing cell death in H. pylori by pyrogallol 3 
is unclear. In agreement with our study active ingredients extracted from traditional 4 
medicinal plants exhibited potent antibacterial activity against H.pyroli [29]. 5 
After 24 h of treatment with ACE or pyrogallol HT-29 and CRL-1831 cells 6 
showed dose dependent decline in cell survival (Fig. 3A and 3B). Interestingly HT-29 7 
cells are more sensitive to pyrogallol with an IC50 value of 35 µg/ml. High chemo 8 
sensitivity of pyrogallol towards HT-29 cells is unclear. However the observed 9 
cytotoxicity of pyrogallol can be inferred based on structure activity relationship. It is 10 
well reported that dihydroxylated phenolic compounds shown less cytotoxicity than 11 
orthotrihydroxylated phenolic compounds in breast cancer (MCF-7 cells) [31]. Hydroxyl 12 
groups can intercalate with DNA and execute irreversible DNA damage and it leads to 13 
nuclear fragmentation. Phenolic compounds are well reported as an inducer of apoptosis 14 
in HEK293T and K562 cells [32]. In our study, observed cytotoxicity of pyrogallol on 15 
HT-29 cells due to its phenolic nature with three hydroxyl group at ortho position in ring. 16 
Based on the structure of pyrogallol we hypothesize that molecular mechanism of 17 
inducing cell death by pyrogallol on HT-29 cells due to nuclear fragmentation and 18 
apoptosis. To address this issue in this study we monitored HT-29 and CRL-1831 cells 19 
for apoptotic morphology and nuclear fragmentation by acridine orange/ethidium 20 
bromide and DAPI staining after 24 h of ACE or pyrogallol treatment. HT-29 and CRL-21 
1831 cells reached necrotic and apoptotic state with treatment of ACE or pyrogallol (Fig. 22 
4A and B). In particular more number of pyrogallol treated HT-29 cells reached dead 23 
state compared to CRL-1831 cells. It indicates that specific chemo sensitive property of 24 
pyrogallol on HT-29 cells. Further DAPI staining reveals that pyrogallol treatment elicits 25 
significant change in nucleus morphology in the form of crescents around the periphery 26 
of the nucleus or the entire chromatin was present as one or a group of featureless, bright 27 
spherical beads compared to ACE (Fig. 4A and B). This nuclear morphological features 28 
clearly indicates the induction of apoptosis. Biochemical signatures accompanied with 29 
apoptosis include chromosomal DNA cleavage into inter-nucleosomal fragments, 30 
phosphatidylserine externalization and a number of intracellular substrate cleavages by 31 
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specific proteolysis (Cohen et al., 1994) [33]. To ensure the extent of DNA damage, in 1 
this study, CRL-1831 and HT-29 cells were treated with ACE or pyrogallaol for 24 h and 2 
DNA ladder formation was examined by electrophoresis. Fig. 5 shows that ACE or 3 
pyrogallol induced dose dependent DNA damage in HT-29 cells compare to CRL-1831 4 
cells [33].   5 
Chemotherapeutic agent triggers apoptosis with irreversible death of cancer cells 6 
is a promising drug candidate [34]. Apoptosis is induced by two alternative pathways, an 7 
extrinsic pathway mediated by the death receptor and the intrinsic pathway mediated by 8 
mitochondria [35, 36]. In the intrinsic pathway, Bcl-2 family includes key regulators of 9 
apoptosis and the molecule is over-expressed in many types of cancer cells [37]. 10 
Mitochondria activated by proapoptotic Bcl-2 family members (Bax, Bak, Bid, etc.) with 11 
release of cytochrome c [38]. Reduced Bcl-2 expression accompanied with high 12 
expression of Bax and cytochrome c may promote apoptotic response to anticancer drugs, 13 
increased expression of Bcl-2 leads to resistance to chemotherapeutic drugs [39]. To 14 
reveal the molecular mechanism of apoptosis induced by ACE or pyrogallol in HT-29 15 
cells, in this study expression of Bcl-2, BAX and cytochrome c were analysed by 16 
immunoblot. Both ACE and pyrogallol decline Bcl-2 expression in HT-29 cells dose 17 
dependently whereas BAX and cytochrome c expression were up regulated (Fig. 6A and 18 
B). These findings suggest that the ACE and pyrogallol induced apoptosis in HT-29 cells 19 
via down regulating the apoptosis activator Bcl-2 with high expression of cytochrome c 20 
which leads to formation of apoptosome in the cytosol and initiation of caspase signaling 21 
cascade. This might be due to free radical scavenging potential of ACE or pyrogallol. 22 
Similarly, luteolin an antioxidant induces apoptosis in HT-29 cells by upregulating Bax, 23 
down regulating Bcl-2, and inducing the release of cytochrome c from mitochondria to 24 
the cytosol [40]. 25 
 Cell cycle checkpoints are important control mechanisms that ensure the proper 26 
execution of cell cycle events which leads to cell proliferation. S and G2/M checkpoint 27 
blocks the entry into mitosis when DNA is damaged [41]. Protein p53 can regulate the 28 
G2/M transition either through the induction of p21 and 14-3-3σ, a protein that normally 29 
sequesters cyclin B1-Cdc2 complexes in the cytoplasm [42, 43] or through the induction 30 
of apoptosis [44, 45]. In our study both ACE and pyrogallol induced significant 31 
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cytotoxicity and apoptosis in HT-29 cells; however the inhibitory role of ACE and 1 
pyrogallol on HT-29 cell cycle remains elusive. To reveal this HT-29 cells were analyzed 2 
for cell cycle after 24 h of treatment with ACE or pyrogallol. We found that both ACE 3 
and pyrogallol is able to arrest S and G2/M phase of cell cycle in a dose dependent 4 
manner (Fig. 7A and 6B). Data suggests that both ACE and pyrogallol halt the S and 5 
G2/M stage of cell division where DNA synthesis and cell division were initiated. 6 
Molecular mechanism of cell cycle arrest induced by ACE or pyrogallol is not clear. 7 
Previously it was demonstrated that pyrogallol induces G2/M arrest in human lung cancer 8 
cells [46]. Phenolic compound treatment arrest S phase of cell cycle in prostate 9 
carcinoma DU145 cells and G2/M phase arrest in HeLa cells accompanied by mitotic 10 
catastrophe, and formation of cells with multiple nuclei, followed by impaired 11 
centrosomal clustering [47, 48]. Further Snchez-Carranza et al. reported that phenolic 12 
compounds isolated from Caesalpinia coriaria induce S and G2/M phase cell cycle arrest 13 
by inhibiting microtubule [49]. These reports are in agreement with our results both ACE 14 
and pyrogallol are phenolic compounds arrest the cell cycle at S and G2/M phase in HT-15 
29 cells possibly by inhibiting microtubule function however, further research in needed 16 
to test this hypothesis. Cancer cell migration is an imperative step before the formation of 17 
micro or macro metastasis. Chemotherapeutic agent halt the migration of cancer cells can 18 
be an ideal drug candidate to arrest metastasis. In this study we performed in vitro wound 19 
healing assay to assess anti migration property of ACE or pyrogallol on HT-29 cells. We 20 
found that 24 h treatment of ACE or pyrogallol restricts the migration of HT-29 cells 21 
significantly (Fig. 8A and 7B). However the molecular mechanism of migration 22 
inhibition by ACE or pyrogallol is unclear. Basically loss of adhesion molecule E-23 
cadherin facilitates early detachment from primary tumor and migration of tumor cells 24 
[50]. Molecules can upregulate the expression of E-cadherin could be an ideal anti 25 
metastatic agent. Phenolic compound such as curcumin inhibited the colon cancer cells 26 
(SW620) migration by upregulating E-cadherin expression [51]. Our previous study 27 
reveals that polyphenol crocin inhibited melanoma metastasis by up regulating the E-28 
cadherin expression [52]. Bases on these previous reports we speculate that both ACE 29 
and pyrogallol might play pivotal role in modulation of E-cadherin expression in HT-29 30 
cells however, this hypothesis should be addressed experimentally with conclusive data. 31 
  
 17 
In conclusion A. nilotica extract and its active constituent pyrogallol inhibited the 1 
growth of carcinogenic H.pylori. Both ACE and pyrogallol elicited significant 2 
cytotoxicity on HT-29 cells by sparing normal colon epithelial cells (CRL-1831) with 3 
minimal toxicity. Pyrogallol induced apoptosis, nuclear fragmentation and arrest S and 4 
G2/M phase of cell cycle in HT-29 cells. Further pyrogallol exhibited in vitro anti 5 
metastatic potential by inhibiting the migration of HT-29 cells. However, the molecular 6 
mechanism of anti cancer potential of pyrogallol should be studied in detail. 7 
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Figure 1: Characterization of Purified pyrogallol from Acacia nilotica  1 
 2 
Isolated pyrogallol characterized by spectral analysis. a) FTIR b) GC MS, c) 1H NMR, d) 3 
13C NMR, e) LC-MS, f) HPLC, g) P.XRD 4 
5 
  
 24 
Figure 2: Flow cytometry dot plots of antibiotics Resistant H. pylori 26695 treated 1 
with ACE extract and pyrogallol 2 
ACE treated H. pylori (A), pyrogallol treated H. pylori (B).Antibiotic resistant H.pylori 3 
treated with ACE (20 µg/ml) and pyrogallol (10 µg/ml) for 3h. H. Pylori stained with 4 
Annexin FITC-A and observed for distribution of cells for 3h with time intervals of 1h. 5 
6 
  
 25 
Figure 3: Cytotoxicity of ACE and pyrogallol on HT-29 cells and CRL-1831 cells 1 
 2 
 3 
Data presented as mean ± STD of triplicates of three independent experiments. HT-29 4 
and CRL-1831 cells treated with various concentration of ACE and pyrogallol for 24 h 5 
and cytotoxicity was determined by MTT assay. A. Normal colon epithelial cells (CRL 6 
1831), B. Colon cancer cells (HT-29).  7 
8 
  
 26 
Figure 4: Apoptotic effect of ACE and pyrogallol on HT-29 cells and CRL-1831 cells 1 
   2 
 3 
 4 
ACE treated cells (A), pyrogallol treated cells (B). Ph- Phase contrast image of a) 5 
Untreated control b) 25 μg/ml c) 50 μg/ml d) 100 µg/ml. Changes in cellular morphology 6 
was observed after 24 h of treatment. AO/EtBr fluorescent staining used to analyze the 7 
apoptotic morphology. Green: live cells, Yellow: necrotic cells, Red: dead cells. DAPI 8 
staining used to observe the nuclear fragmentation. Magnification at 20X. 9 
 10 
 11 
 12 
 13 
 14 
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 27 
Figure 5 : Induction of DNA Fragmentation in CRL-1831 and HT-29 cells  1 
 2 
 3 
 4 
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 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
CRL-1831 and HT-29 cells were treated with ACE or Pyrogallol (0, 25, 50 and 100 19 
μg/ml) for 24 h. DNA was isolated and resolved in agarose gel and examined by ethidium 20 
bromide staining. 21 
 22 
23 
  
 28 
Figure 6: Western Blot Analysis of Bcl-2, Bax and cytochrome c 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
Whole cell lysate prepared from ACE or pyrogallol treated HT-29 cells. ACE and 17 
pyrogallol treatment resulted dose dependent decline in Bcl-2 expression and increase in 18 
BAX and cytochrome c expression. β-actin as a loading control.  19 
20 
  
 29 
Figure 7: Determination of Cell Cycle Arrest by ACE and Pyrogallol on HT-29 cells 1 
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 32 
ACE treated cells (A), pyrogallol treated cells (B). 2 X 105 HT-29 cells were treated with 33 
ACE and pyrogallol for 24 h. a) Untreated control b) 25 μg/ml c) 50 μg/ml d) 100 µg/ml. 34 
Cells were harvested and stained with propidium iodide as described. Experiment 35 
repeated thrice and the profile was similar. 36 
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 30 
Figure 8: Wound Healing Property of ACE and Pyrogallol on HT-29 cells 1 
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 34 
 35 
ACE treated cells (A), pyrogallol treated cells (B). HT29 cells were injured and cell 36 
migration assay with and without treatment of ACE or pyrogallol (25 and 50 µg/ml) was 37 
performed. ACE or pyrogallol treated HT29 cells lost the migration ability compare to 38 
untreated control. Magnification: 20X. Data presented as mean ± STD of triplicates of 39 
three independent experiments. * indicates the significant difference at p<0.01. 40 
 41 
 42 
 43 
 44 
